Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1368 ARTÍCULOS , VIENDO DEL 31 AL 45

Aberrant Neuronal Cell Cycle Re-Entry: The Pathological Confluence of Alzheimer's Disease and Brain Insulin Resistance, and Its Relation to Cancer

Koseoglu MM, Norambuena A, Sharlow ER, Lazo JS, Bloom GS.

J Alzheimers Dis. 2019;67(1):1-11. doi: 10.3233/JAD-180874.

Impact of Antidepressant Use on the Trajectory of Alzheimer's Disease: Evidence, Mechanisms, and Therapeutic Implications

Khoury R, Grossberg GT.

CNS Drugs. 2019 Jan;33(1):17-29. doi: 10.1007/s40263-018-0590-9.

The impact of anorexigenic peptides in experimental models of Alzheimer's disease pathology

Maletínská L, Popelová A, Železná B, Bencze M, Kuneš J.

J Endocrinol. 2019 Feb 1;240(2):R47-R72. doi: 10.1530/JOE-18-0532.

Systematic Multi-Domain Alzheimer's Risk Reduction Trial (SMARRT): Study Protocol

Yaffe K, Barnes DE, Rosenberg D, Dublin S, Kaup AR, Ludman EJ, Vittinghoff E, Peltz CB, Renz AD, Adams KJ, Larson EB.

J Alzheimers Dis. 2019;70(s1):S207-S220. doi: 10.3233/JAD-180634.

Ethical Issues in the Treatment of Late-Stage Alzheimer's Disease

Watt AD, Jenkins NL, McColl G, Collins S, Desmond PM.

J Alzheimers Dis. 2019;68(4):1311-1316. doi: 10.3233/JAD-180865.

Recent Advances in Multi-target Anti-Alzheimer Disease Compounds (2013 Up to the Present)

Wang N, Qiu P, Cui W, Yan X, Zhang B, He S.

Curr Med Chem. 2019;26(30):5684-5710. doi: 10.2174/0929867326666181203124102.

Tau Abnormalities and the Potential Therapy in Alzheimer's Disease

Almansoub HAMM, Tang H, Wu Y, Wang DQ, Mahaman YAR, Wei N, Almansob YAM, He W, Liu D.

J Alzheimers Dis. 2019;67(1):13-33. doi: 10.3233/JAD-180868.

The role of neurovascular unit damage in the occurrence and development of Alzheimer's disease

Liu X, Hou D, Lin F, Luo J, Xie J, Wang Y, Tian Y.

Rev Neurosci. 2019 Jul 26;30(5):477-484. doi: 10.1515/revneuro-2018-0056.

Sex Differences in Alzheimer's Disease: Where Do We Stand?

Medeiros AM, Silva RH.

J Alzheimers Dis. 2019;67(1):35-60. doi: 10.3233/JAD-180213.

Organotypic Brain Slices of ADULT Transgenic Mice: A Tool to Study Alzheimer's Disease

Humpel C.

Curr Alzheimer Res. 2019;16(2):172-181. doi: 10.2174/1567205016666181212153138.

Stem cell therapies for Alzheimer's disease: is it time?

Wang SM, Lee CU, Lim HK.

Curr Opin Psychiatry. 2019 Mar;32(2):105-116. doi: 10.1097/YCO.0000000000000478.

AADvac1, an Active Immunotherapy for Alzheimer's Disease and Non Alzheimer Tauopathies: An Overview of Preclinical and Clinical Development

Novak P, Zilka N, Zilkova M, Kovacech B, Skrabana R, Ondrus M, Fialova L, Kontsekova E, Otto M, Novak M.

J Prev Alzheimers Dis. 2019;6(1):63-69. doi: 10.14283/jpad.2018.45.

Death-Associated Protein Kinase 1 as a Promising Drug Target in Cancer and Alzheimer's Disease

Chen D, Zhou XZ, Lee TH.

Recent Pat Anticancer Drug Discov. 2019;14(2):144-157. doi: 10.2174/1574892814666181218170257.

Intranasal Delivery of Nanotherapeutics/ Nanobiotherapeutics for the Treatment of Alzheimer's Disease: A Proficient Approach

Dhas NL, Kudarha RR, Mehta TA.

Crit Rev Ther Drug Carrier Syst. 2019;36(5):373-447. doi: 10.1615/CritRevTherDrugCarrierSyst.2018026762.

Personality and Alzheimer's disease: An integrative review

Terracciano A, Sutin AR.

Personal Disord. 2019 Jan;10(1):4-12. doi: 10.1037/per0000268.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias